In summary, the observed differences in uveitis prevention between etanercept and monoclonal TNF-α inhibitors likely arise from their selective binding to sTNF-α/mTNF-α, their differential blockade of receptor pathways, and variations in ocular drug distribution. This evidence concerns the gene TNF and uveitis.